Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Amgen Inc.
IndexS&P 500 P/E21.51 EPS (ttm)6.53 Insider Own0.10% Shs Outstand759.61M Perf Week-0.16%
Market Cap106.69B Forward P/E15.63 EPS next Y8.99 Insider Trans4.98% Shs Float758.78M Perf Month0.77%
Income5.01B PEG2.17 EPS next Q2.10 Inst Own81.60% Short Float1.60% Perf Quarter16.75%
Sales19.46B P/S5.48 EPS this Y20.30% Inst Trans-1.05% Short Ratio3.89 Perf Half Y12.03%
Book/sh32.12 P/B4.37 EPS next Y6.91% ROA7.70% Target Price144.40 Perf Year27.37%
Cash/sh34.48 P/C4.07 EPS next 5Y9.90% ROE22.00% 52W Range104.22 - 144.46 Perf YTD24.43%
Dividend2.44 P/FCF22.90 EPS past 5Y12.00% ROI10.50% 52W High-2.77% Beta0.54
Dividend %1.74% Quick Ratio4.00 Sales past 5Y4.50% Gross Margin80.50% 52W Low34.78% ATR2.29
Employees20000 Current Ratio4.40 Sales Q/Q10.70% Oper. Margin33.80% RSI (14)57.39 Volatility1.88% 1.67%
OptionableYes Debt/Eq1.37 EPS Q/Q21.80% Profit Margin25.70% Rel Volume0.84 Prev Close140.07
ShortableYes LT Debt/Eq1.26 EarningsOct 20 AMC Payout32.60% Avg Volume3.12M Price140.46
Recom2.30 SMA200.50% SMA505.36% SMA20015.66% Volume2,618,300 Change0.28%
08-Sep-14Reiterated RBC Capital Mkts Outperform $138 → $150
04-Aug-14Reiterated Argus Buy $135 → $140
30-Jul-14Reiterated RBC Capital Mkts Outperform $125 → $138
18-Jul-14Reiterated Deutsche Bank Buy $144 → $149
23-Apr-14Reiterated Oppenheimer Perform $121 → $122
21-Mar-14Reiterated Barclays Equal Weight $115 → $130
31-Jan-14Reiterated Argus Buy $130 → $135
20-Nov-13Reiterated Deutsche Bank Buy $138 → $142
29-Aug-13Reiterated UBS Buy $121 → $124
27-Aug-13Reiterated Barclays Overweight $105 → $115
31-Jul-13Reiterated Oppenheimer Perform $100 → $109
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
02-Aug-12Downgrade Argus Buy → Hold
15-Mar-12Resumed Stifel Nicolaus Hold
30-Sep-14 12:06PM  Amgen, Inc. Showing Strong Performance Despite Low Beta Benzinga
29-Sep-14 07:03PM  SEC lawsuit over Onyx insider trading can move forward -U.S. judge Reuters
04:00PM  Amgen Inc Conference Call on Kyprolis at ESMO scheduled for 4:00 pm ET today CCBN
01:03PM  AMGN, ACT And GILD, Pushing Drugs Industry Downward at TheStreet
26-Sep-14 04:20PM  Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 Zacks
25-Sep-14 05:17PM  Biotech selloff: What to buy CNBC
05:17PM  [video] Biotech selloff: What to buy at CNBC
04:00PM  Inovio/GeneOne Life Science Collaborate for Ebola Vaccine Zacks
02:19PM  4 picks in biotech Yahoo Finance
08:31AM  Zacks Rank #1 Additions for Thursday Zacks
24-Sep-14 05:02PM  Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress PR Newswire
04:30PM  Celgene's Otezla Label Expanded to Include Plaque Psoriasis Zacks
01:27PM  Acorda To Buy Civitas, Gains Parkinson's Disease Drug at Investor's Business Daily
09:01AM  For Second Act, Acorda Drops $525 Million On Inhaled Parkinson's Drug at Forbes
02:30AM  ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise PR Newswire
23-Sep-14 03:45PM  Bayer/Regeneron Successfully Expand Eylea Label in Japan Zacks
22-Sep-14 09:00AM  Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab PR Newswire
19-Sep-14 05:26PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
18-Sep-14 05:24PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
04:35PM  Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies Zacks
17-Sep-14 06:15PM  Merck Posts Positive Data on Osteoporosis Drug Odanacatib Zacks
05:40PM  UCB-Amgen Reveals Positive Data on Romosozumab for PMO Zacks
05:12PM  The Market's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
02:34PM  Amgen, Inc. Poised To Break Higher Benzinga
15-Sep-14 05:06PM  Biotech still place to be: Pro CNBC
05:06PM  [video] Biotech still place to be: Pro at CNBC
04:50PM  Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Zacks
04:30PM  Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis PR Newswire
04:00PM  New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density PR Newswire
09:30AM  A Fabulous Pharma ETF ETF Trends
14-Sep-14 09:00PM  Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure PR Newswire
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
03:30PM  Orexigen's Obesity Drug Contrave Approved by the FDA Zacks
09:20AM  Short Sellers Remain Vigilant Against Biotechs at 24/7 Wall St.
08:54AM  UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare Conference Benzinga
07:59AM  The Zacks Analyst Blog Highlights: AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen Zacks
10-Sep-14 06:20PM  [video] Marathon Oil, Amgen Smart Long Haul Stocks Says Forester Fund Manager at TheStreet
04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
04:06PM  Amgen, Inc. Showing More Upside Potential Benzinga
03:55PM  Xenoport/NIAAA Collaborate on Alcoholism Therapy Zacks
02:00PM  Myriad Genetics Posts Encouraging myPath Melanoma Data Zacks
10:17AM  Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval Zacks
09:18AM  Zacks Rank #1 Additions for Wednesday Zacks
09:15AM  Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting PR Newswire
08-Sep-14 01:10PM  Five Reason Amgen Won't Be Breaking Up at Barrons.com
05-Sep-14 04:04PM  Amgen To Present At The Morgan Stanley Global Healthcare Conference PR Newswire
09:27AM  Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding Benzinga
04-Sep-14 05:00PM  Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Zacks
11:01AM  Celgene: Good Data But What About the Patent Challenges? at Barrons.com
03-Sep-14 05:40PM  Sanofi Reports Positive Phase III Data on Dengue Vaccine Zacks
04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
02-Sep-14 07:36PM  Biotech Helps Drive Broad Market at Investor's Business Daily
05:39PM  Today's Thorns, Roses and All Time Highs in the Markets... Yahoo Finance Blogs
03:44PM  [video] The cholesterol race at CNBC
03:04PM  [video] Jim Cramer Says Regeneron is a Better Way to Play it Than Sanofi at TheStreet
01:34PM  [video] Biotech's $10 billion opportunity at CNBC
01:00PM  [video] American doctor tests for Ebola: Report at CNBC
11:19AM  Novartis, Regeneron Hit New Highs On Cardio Drugs at Investor's Business Daily
08:17AM  [video] Race for cholesterol drugs at CNBC
08:15AM  Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency PR Newswire
08:00AM  Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency PR Newswire
31-Aug-14 10:30AM  Study raises concerns over Servier, Amgen heart drug Reuters
03:00AM  Early data suggest Sanofi, Regeneron drug may halve heart risk Reuters
30-Aug-14 08:31AM  The Most Interesting Man Revolutionizing The Health World at Forbes
07:00AM  New Novartis Drug Effective in Treating Heart Failure at New York Times
28-Aug-14 06:42PM  Amgen edges up on trial results Investor's Business Daily
05:20PM  Amgen's Chronic Heart Failure Drug Gets Priority Review Zacks
03:17PM  Amgen: Why Its New Drug Application is a Big Deal at Barrons.com
03:17PM  Amgen: Why Its New Drug Application is a Bid Deal at Barrons.com
12:08PM  Amgen seeks U.S. approval of new cholesterol-fighting drug Reuters
09:45AM  Amgen submits U.S. application to sell cholesterol-fighting drug Reuters
09:15AM  Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol PR Newswire
09:00AM  Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA PR Newswire
08:31AM  BioDelivery Sciences (BDSI) Jumps: Stock Moves 5.6% Higher Zacks
27-Aug-14 11:45AM  Who are Amgen Inc.'s (AMGN) main competitors? at Investopedia
10:32AM  Why Amgen (AMGN) Stock Hit a One-Year High Today at TheStreet
10:12AM  [$$] Amgen Heart Drug Gets FDA Priority at The Wall Street Journal
09:15AM  FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure PR Newswire
26-Aug-14 05:44PM  Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study Zacks
05:00AM  'Fast Money' Recap: Next Stop, S&P 2,100? at TheStreet
25-Aug-14 09:49AM  [video] Gilead 'the drug story': Cramer at CNBC
22-Aug-14 03:40PM  Amgen Upgraded to Strong Buy Zacks
21-Aug-14 01:20PM  Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Reuters
08:55AM  Lilly psoriasis drug fares well in late-stage test AP
20-Aug-14 03:27PM  Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy Zacks
10:08AM  Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Zacks
19-Aug-14 04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
09:50AM  A New Cannabinoid-based Arthritis Therapy in the Making Accesswire
08:55AM  Amgen parathyroid drug succeeds in late-stage trial (Aug 18) Reuters
08:07AM  Morning Movers: Home Depot Jumps on Big Beat; Aeropostale Climbs on New CEO at Barrons.com
07:07AM  [video] Hot biotech drugs at CNBC
01:55AM  Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company PR Newswire
18-Aug-14 11:21PM  Nasdaq hits highest level since March 2000 at USA TODAY
05:55PM  Amgen thyroid drug succeeds in late-stage trial Reuters
05:17PM  Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis PR Newswire
04:10PM  Ligand Up on Multi-Program Captisol Deal with Avion Pharma Zacks
03:35PM  4 Large-Cap Healthcare Stocks To Watch at Investopedia
15-Aug-14 08:03AM  The Zacks Analyst Blog Highlights: Amgen, ANN, Citi Trends, Men's Wearhouse and Kate Spade Zacks
12:00AM  Amgen Market Value Playing Catch-Up to Shares: Chart of the Day at Bloomberg
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM